Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. The company stated a philosophy of investing in capex if opportunities arise but did not indicate any planned fundraising. They mentioned an ongoing gradual deleveraging strategy following improved operating performance, implying no immediate need for additional debt. There is a strategic investment by Eight Roads into the biotech arm, but this appears to be an existing partnership rather than a new fundraising round. The company plans to invest around INR40 crores before June 2

Any current/future capex/capital investment/strategic investment?

Laurus Labs opened a new R&D center last quarter, equal in size to the current R&D, to handle more molecules and early-stage programs. Further augmentation of scientific talent is planned for more clinical programs. Capex philosophy: Investment will continue if opportunities arise; no fixed reduction plan. Investing around INR120 crores in a CGT (cell and gene therapy) GMP facility expected in FY '26, catering to viral vectors and plasmid manufacture. Two large-scale bio capacity facilities under construction: one in Vizag (operational by end of 2026) and another in Mysore. A 400 KL fe

Future growth expectations in sales/revenue/volumes?

CDMO division expects continued robust growth in FY '26 and beyond, with a well-diversified pipeline of late-stage clinical programs. No specific quantification for FY '26 sales, but prospects in CDMO are very bright with anticipated substantial growth over FY '25. Formulation and API businesses expected to see significant medium-term growth, possibly starting FY '27, as the pipeline broadens. Bio division growth expected to be limited in FY '26 due to capacity debottlenecking but anticipated to see big growth from FY '27 onwards. Animal health and CropScience segments to experience significan

Future growth expectations in earnings/operating earnings/profits/EPS?

Laurus Labs expects continued growth in their CDMO business, with FY '26 anticipated to be better than FY '25, though exact revenue or margin guidance is not provided. The Bio division is expected to show significant growth starting FY '27, after capacity expansions complete by end of 2026; FY '26 is likely to see minimal growth. Formulation and API segments are not expected to see quantum jumps in FY '26 but are projected to grow significantly in the medium term, possibly from FY '27 onward. The company's EBITDA margin target for the full financial year remains close to 20%, with progre

Current/ Expected Orderbook/ Pending Orders?

The company has a robust pipeline with multiple ongoing projects in the CDMO division, including more than 70 projects featuring breakthrough designated molecules. CDMO division recorded its highest quarterly sales in the last 8 quarters, close to INR 400 crores, with a 33% growth over 9 months, indicating strong demand and order flow. Multiple commercial launch quantities and registration batches were supplied in Q3 and Q4 for several products, showcasing diversified and growing orderbook. The company continues to receive encouraging RFPs (Request for Proposals) and is signing early to mid-st

IN US

Sale is live|00:00:00left today

Laurus Labs LtdQ4 FY26Pharmaceuticals & Biotechnology

Laurus Labs Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,450P/E: 80.4Market Cap: ₹71.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→CDMO division expects continued robust growth in FY '26 and beyond, with a well-diversified pipeline of late-stage clinical programs.
→No specific quantification for FY '26 sales, but prospects in CDMO are very bright with anticipated substantial growth over FY '25.
→Formulation and API businesses expected to see significant medium-term growth, possibly starting FY '27, as the pipeline broadens.
→Bio division growth expected to be limited in FY '26 due to capacity debottlenecking but anticipated to see big growth from FY '27 onwards.
→Animal health and CropScience segments to experience significant growth next year.
→The GMP gene therapy viral vector manufacturing facility to start contributing commercially from FY '26.
→ARV franchise revenues expected to stabilize around INR 2,300-2,500 crores per annum.
→Capex investments will continue as per opportunities to support growth.

Margin guidance

Category 3

→Laurus Labs expects continued growth in their CDMO business, with FY '26 anticipated to be better than FY '25, though exact revenue or margin guidance is not provided.
→The Bio division is expected to show significant growth starting FY '27, after capacity expansions complete by end of 2026; FY '26 is likely to see minimal growth.
→Formulation and API segments are not expected to see quantum jumps in FY '26 but are projected to grow significantly in the medium term, possibly from FY '27 onward.
→The company's EBITDA margin target for the full financial year remains close to 20%, with progressive improvement expected in Q4.
→Growth from multiple products and diversification in the CDMO segment is expected to provide sustainable revenue streams.
→No explicit EPS or profit figures are provided, but the management expresses confidence in value creation and improved operating leverage going forward.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
→The company stated a philosophy of investing in capex if opportunities arise but did not indicate any planned fundraising.
→They mentioned an ongoing gradual deleveraging strategy following improved operating performance, implying no immediate need for additional debt.
→There is a strategic investment by Eight Roads into the biotech arm, but this appears to be an existing partnership rather than a new fundraising round.
→The company plans to invest around INR40 crores before June 2025 in the Bio segment alongside partners but did not specify this as new fundraising.
→Overall, no direct announcements or plans for raising new debt or equity were disclosed during the call.

Order book

Yes

→The company has a robust pipeline with multiple ongoing projects in the CDMO division, including more than 70 projects featuring breakthrough designated molecules.
→CDMO division recorded its highest quarterly sales in the last 8 quarters, close to INR 400 crores, with a 33% growth over 9 months, indicating strong demand and order flow.
→Multiple commercial launch quantities and registration batches were supplied in Q3 and Q4 for several products, showcasing diversified and growing orderbook.
→The company continues to receive encouraging RFPs (Request for Proposals) and is signing early to mid-stage projects involving complex chemistry.
→Augmentation of R&D and scientific talent is being done to handle more clinical programs and pipelines.
→Capex investments continue to be made opportunistically to support growth projects and new facility capacities.
→Overall, the management expresses confidence in sustainable growth backed by a well-diversified and increasing project pipeline.

Capex plans

Yes

→Laurus Labs opened a new R&D center last quarter, equal in size to the current R&D, to handle more molecules and early-stage programs. Further augmentation of scientific talent is planned for more clinical programs.
→Capex philosophy: Investment will continue if opportunities arise; no fixed reduction plan.
→Investing around INR120 crores in a CGT (cell and gene therapy) GMP facility expected in FY '26, catering to viral vectors and plasmid manufacture.
→Two large-scale bio capacity facilities under construction: one in Vizag (operational by end of 2026) and another in Mysore.
→A 400 KL fermentation capacity being created mainly for internal use, not for partners.
→Strategic investment by Eight Roads in the biotech arm; Laurus and partners to invest additional INR40-35 crores by June 2025.
→Capex of INR3,000 crores since FY '22, with about half yet to be commercialized; further capex will be over and above this.

How does Laurus Labs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Laurus Labs Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Laurus Labs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio